Baricitinib, marketed as Olumiant, is already approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
A final decision from the European Commission is expected in the one or two months.
Price: 153.55, Change: +1.08, Percent Change: +0.71
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|